# Comparability after manufacturing changes

Source: https://onco.cc/terms/manufacturing-process-comparability/  
OnCo record `manufacturing-process-comparability` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A changed manufacturing process needs evidence about the product before and after the change. Comparability asks whether observed differences could matter to product quality, safety or effectiveness.

## Summary

ICH Q5E provides a framework for comparing a biological product before and after manufacturing changes. It emphasizes quality attributes and assessing whether additional nonclinical or clinical evidence is needed. It does not prescribe one universal testing strategy. The question concerns a specified process change and product; it should not be collapsed into a general claim that all batches, sites or related products are interchangeable. Q5E states that comparability does not necessarily mean the pre-change and post-change attributes are identical, but that they are highly similar and existing knowledge is predictive enough that differences have no adverse impact on safety or efficacy. For autologous CAR T cells FDA's 2024 guidance says historical lots may be inadequate and recommends side-by-side testing on the same starting material where possible, for example one leukapheresis split between the pre-change and post-change processes. FDA's July 2023 manufacturing-changes and comparability guidance for cellular and gene therapy products is still labelled draft, not for implementation, on FDA's page checked 9 November 2026.

## Fields

- Kind: Term
- Last checked: 2026-11-10
- Also known as: manufacturing process comparability; process-change comparability

## Notes

- Comparable does not mean identical. Q5E says comparability shows that pre-change and post-change product are highly similar and that existing knowledge predicts that any differences have no adverse impact on safety or efficacy. First describe what changed and which properties it might alter, then use methods able to detect those effects. FDA's CAR T guidance says meeting current lot-release criteria is typically insufficient to establish comparability, and Q5E notes that stability studies can reveal subtle differences.
- Where suitable, the same starting material can be split between the old and new process, for example one leukapheresis divided between pre-change and post-change manufacture (FDA CAR T guidance). This reduces one source of variation but does not erase all uncertainty or replace an adequate study design; healthy-donor material may be used in some studies, with patient-versus-donor differences considered.
- Measurement caution. An assay change can itself create an apparent product difference, which is why FDA's potency guidance has sections on reference materials and on assay changes and transfers. The CAR T guidance asks for predefined acceptance criteria and appropriate statistical methods. A nonsignificant test alone does not establish similarity, because an insensitive comparison can miss an important difference; this is an inference from the need for predefined criteria and sensitive methods.
- Q5E says the evaluation should indicate whether confirmatory nonclinical or clinical studies are appropriate. Inference lesson: if cell counts match after a medium change but a relevant T-cell subset shifts substantially, count is one attribute, so the subset, function and other plausibly affected properties must be assessed before earlier evidence is called relevant. A process bridge is not head-to-head equivalence between different therapies. FDA's July 2023 comparability guidance for cellular and gene therapy products was still labelled draft, not for implementation, on FDA's page read on 9 November 2026.
- Personalisation does not give a new sequence or an edited process an automatic bridge to every earlier result. A platform may deliberately vary antigen sequence under defined controls, and each change still has to be assessed for its effect on the product.

## Sources

- EMA/ICH Q5E: comparability after a manufacturing-process change: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-5-e-comparability-biotechnologicalbiological-products-step-5_en.pdf
- FDA/ICH Q5E: comparability of biotechnological/biological products (June 2005): https://www.fda.gov/media/71489/download
- FDA: considerations for the development of CAR T cell products (January 2024), comparability section: https://www.fda.gov/media/156896/download

## Connected records

- terms: [Certificate of analysis](https://onco.cc/terms/certificate-of-analysis/), [Chemistry, manufacturing and controls](https://onco.cc/terms/chemistry-manufacturing-controls/), [Immune measurements and product evidence](https://onco.cc/terms/immune-product-evidence/), [Vein-to-vein time and manufacturing slots](https://onco.cc/terms/vein-to-vein-time/)
- technologies: [Biosimilar manufacturing and comparability](https://onco.cc/technologies/biosimilar-manufacturing/), [Cell-therapy release and potency testing](https://onco.cc/technologies/cell-therapy-release-testing/)

---
JSON: https://onco.cc/api/v1/entities/manufacturing-process-comparability.json